


# 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19

Sam Schulman<sup>1,2</sup>  | Donald M. Arnold<sup>1,3</sup> | Charlotte A. Bradbury<sup>4</sup> |  
 Lisa Broxmeyer<sup>5</sup> | Jean Marie Connors<sup>6</sup> | Anna Falanga<sup>7,8</sup> | Toshiaki Iba<sup>9</sup> |  
 Scott Kaatz<sup>10</sup> | Jerrold H. Levy<sup>11</sup> | Saskia Middeldorp<sup>12</sup> | Tracy Minichiello<sup>13</sup> |  
 Ishac Nazy<sup>1,3</sup> | Eduardo Ramacciotti<sup>14,15</sup> | Helaine E. Resnick<sup>16</sup> |  
 Charles Marc Samama<sup>17</sup> | Michelle Sholzberg<sup>18</sup> | Jecko Thachil<sup>19</sup> |  
 Ryan Zarychanski<sup>20</sup> | Alex C. Spyropoulos<sup>5,21</sup> | on behalf of the International Society on  
 Thrombosis and Haemostasis

<sup>1</sup>Department of Medicine, McMaster University, Hamilton, Ontario, Canada

<sup>2</sup>Department of Obstetrics and Gynecology and Perinatal Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

<sup>3</sup>Michael G. DeGroot Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada

<sup>4</sup>Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom

<sup>5</sup>Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA

<sup>6</sup>Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, USA

<sup>7</sup>Department of Transfusion Medicine and Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy

<sup>8</sup>University of Milan Bicocca, Monza, Italy

<sup>9</sup>Department of Emergency and Disaster Medicine, Juntendo University, Tokyo, Japan

<sup>10</sup>Division of Hospital Medicine, Henry Ford Hospital, Detroit, Michigan, USA

<sup>11</sup>Departments of Anesthesiology, Critical Care, and Surgery (Cardiothoracic), Duke University School of Medicine, Durham, North Carolina, USA

<sup>12</sup>Department of Internal Medicine and Radboud Institute of Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands

<sup>13</sup>Division of Hematology, San Francisco VA Medical Center, University of California, San Francisco, San Francisco, California, USA

<sup>14</sup>Science Valley Research Institute, São Paulo, Brazil

<sup>15</sup>Hospital e Maternidade Christóvão da Gama, Grupo Leforte, Santo André, São Paulo, Brazil

<sup>16</sup>Resnick, Chodorow & Associates, Silver Spring, Maryland, USA

<sup>17</sup>Department of Anaesthesia, Intensive Care and Perioperative Medicine, Groupe Hospitalo-Universitaire, Assistance Publique-Hôpitaux de Paris Centre - Université Paris Cité, Cochin Hospital, Paris, France

<sup>18</sup>Departments of Medicine and Laboratory Medicine and Pathobiology, St Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Ontario, Canada

<sup>19</sup>Department of Haematology, Manchester University Hospitals, Manchester, United Kingdom

<sup>20</sup>Sections of Hematology/Oncology and Critical Care, University of Manitoba, Winnipeg, Manitoba, Canada

<sup>21</sup>Institute of Health System Science, Feinstein Institutes for Medical Research, Manhasset, New York, USA

Manuscript handled by: Walter Ageno

Final decision: Walter Ageno, 13 February 2024

© 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

**Correspondence**

Sam Schulman, Thrombosis Service, HHS-General Hospital, 237 Barton Street East, Hamilton, ON L8L2X2, Canada.  
Email: [schulms@mcmaster.ca](mailto:schulms@mcmaster.ca)

**Funding information**

This work was supported by the ISTH.

**Abstract**

Based on emerging evidence from the COVID-19 pandemic, the International Society on Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 were published in 2022. Since then, at least 16 new randomized controlled trials have contributed additional evidence, which necessitated a modification of most of the previous recommendations. We used again the American College of Cardiology Foundation/American Heart Association methodology for assessment of level of evidence (LOE) and class of recommendation (COR). Five recommendations had the LOE upgraded to A and 2 new recommendations on antithrombotic treatment for patients with COVID-19 were added. Furthermore, a section was added to answer questions about COVID-19 vaccination and vaccine-induced immune thrombotic thrombocytopenia (VITT), for which studies have provided some evidence. We only included recommendations with LOE A or B. Panelists agreed on 19 recommendations, 4 for nonhospitalized, 5 for noncritically ill hospitalized, 3 for critically ill hospitalized, and 2 for postdischarge patients, as well as 5 for vaccination and VITT. A strong recommendation (COR 1) was given for (a) use of prophylactic dose of low-molecular-weight heparin or unfractionated heparin in noncritically ill patients hospitalized for COVID-19, (b) for select patients in this group, use of therapeutic-dose low-molecular-weight heparin/unfractionated heparin in preference to prophylactic dose, and (c) for use of antiplatelet factor 4 enzyme immunoassays for diagnosing VITT. A strong recommendation was given against (COR 3) the addition of an antiplatelet agent in hospitalized, noncritically ill patients. These international guidelines provide recommendations for countries with diverse healthcare resources and COVID-19 vaccine availability.

**KEYWORDS**

anticoagulants, COVID-19, COVID-19 vaccines, critical illness, platelet aggregation inhibitors

**1 | PREAMBLE**

The ISTH has published evidence-based clinical practice guidelines since 2020 with recommendations that aim to improve global health. ISTH strives to promote increased adoption of evidence-based guidelines by increasing the speed, quality, access, and applicability of these resources. Guideline panel members volunteer their time to gather and evaluate published literature and to synthesize and classify evidence. Guidelines are official policy of the ISTH.

**1.1 | Target audience**

This guideline provides recommendations for clinicians in Internal Medicine, Intensive Care, Infectious Disease, Hematology, and Vascular Medicine, as well as hospitalists, family practitioners, and other healthcare providers who deliver inpatient or outpatient care to patients with COVID-19. Although guidelines endeavor to apply to a

majority of patients, they can never be relevant to every individual and must be accompanied by good clinical judgment. The ultimate goal is to optimize quality of care while taking patient preferences into account. Clinical practice guidelines may also help inform decision-making among regulatory agencies and payers.

**1.2 | Clinical implementation**

Successful treatment is predicated on effective interactions between the clinical team and the patients they treat. One aspect of these interactions is communicating the value of clinical practice guidelines. Engagement and adherence to treatment are improved among patients who receive education on the evidence underpinning their recommended treatments and among those who engage in shared decision-making with their care teams. Patient values and preferences are particularly important when the quality of the evidence and/or the strength of a recommendation is low.

## 2 | INTRODUCTION

COVID-19 was declared a pandemic on March 11, 2020 [1]. Although the World Health Organization downgraded COVID-19 from this level on May 5, 2023, because it no longer considered it a global emergency, COVID-19 remains prevalent across the globe, with new spikes in cases in 2023 [2]. COVID-19 has claimed almost 7 million lives, yet as of March 2023, 28% of the world population had not received any vaccination against COVID-19, with glaring disparities between highly developed and less developed countries [3]. Although new subvariants of the SARS-CoV-2 Omicron variant appear to cause less severe disease, they are more contagious than previous variants. Persistently high transmission rates, coupled with a large number of community-dwelling individuals at high risk of infection and complications, suggest that clinicians must remain vigilant about COVID-19 and up-to-date on treatment recommendations.

### 2.1 | Purpose of the update

More than a dozen new randomized controlled trials (RCTs) have been published since the original ISTH guidelines for antithrombotic treatment in COVID-19 were published online in July 2022 [4]. To ensure clinicians remain current on emerging evidence, the guideline panel proposed production of a focused update. This proposal was approved by ISTH in March 2023 with a request to add a section on vaccination against COVID-19 and vaccine-induced immune thrombotic thrombocytopenia (VITT). However, during review of the new literature, it became clear that most of the original recommendations required modifications linked to changes in the level of evidence (LOE) and/or the class of recommendation (COR). Furthermore, some questions that did not meet the prespecified evidence threshold for inclusion in the original guideline were now sufficiently supported to warrant new recommendations. Based on these observations, the project shifted from a focused update to a general update of the entire guideline.

Ideally, studies published since mid-2022 would provide COVID-19 variant-specific results, but this was rarely the case. New studies were initiated early in the pandemic and enrolled patients with predominantly or only early variants, or they enrolled patients over several years but did not specify outcomes by COVID-19 variant. Accordingly, it was not possible to report variant-specific recommendations. It could also be argued that the recommendations should be tailored to patients' vaccination status. Again, available data from the RCTs are not sufficiently detailed to inform of differences in management according to patients' vaccination status. Although most patients with recent vaccination will have no or mild symptoms, it is more relevant to tailor treatment recommendations to severity of the illness.

## 3 | METHODS

Consistent with the original guideline, ISTH used methods recommended by the American College of Cardiology Foundation (ACCF)

and the American Heart Association (AHA) [5,6]. These methods keep the guidelines short and user-friendly by presenting each set of recommendations in tabular format, followed by a brief synopsis and recommendation-specific supportive text. Due to the temporal proximity of this update to the original guideline, we do not repeat recommendation-specific supportive text if there was no change in the LOE, COR, or outcomes. For those recommendations, readers are referred to the original version of the guideline.

### 3.1 | Panel selection and management of conflicts of interest

The guideline Chairman, 13 content expert panel members, and 2 patient representatives (L.B. and S.K.) from the original version of the guidelines participated in this update. Two additional content experts were invited to lead the new section on vaccination and VITT. All members completed disclosures including information on relationships with industry and other potential conflicts of interest. Panelists remained in their previously assigned sections (outpatients [nonhospitalized and postdischarge; J.T., T.I., and T.A.M.], noncritically ill patients [A.C.S., S.M., C.A.B., and E.R.], and critically ill patients [R.Z., C.M.S., and J.H.L.]) except 3 who were assigned to the new vaccine and VITT section (M.S., J.M.C., A.F. and the content experts D.M.A. and I.N.). Critically ill and noncritically ill patients were defined based on criteria in each included study, and details are available in the evidence tables. Generally, patients not requiring organ support or mechanical ventilation other than low-flow supplemental oxygen were considered noncritically ill. Although there are relatively few patients with critical illness due to COVID-19, some patients require immediate organ support, such as invasive or noninvasive positive pressure ventilation, high-flow supplemental oxygen therapy, extracorporeal membrane oxygenation, continuous renal replacement therapy, vasopressor, or inotrope support.

### 3.2 | Search strategy and deployment

The literature search algorithm for the recommendations in the 2022 ISTH guidelines for antithrombotic treatment in COVID-19 was used again but with the time period changed from January 1, 2020, to March 06, 2022, March 01, 2022, March 31, 2023. However, for the section on vaccines and VITT, the search, based on extensive input from the guideline panel, included the period April 1, 2023, to August 03, 2023 (PubMed, Cochrane, and EMBASE) and was performed by an experienced medical librarian.

### 3.3 | Abstract review and identification of included studies

For the original recommendations, which with one exception were based on data from RCTs, the working groups only selected and

reviewed abstracts from new RCTs or meta-analyses. Prespecified criteria included the updated date range, human subjects aged 18+ years, established COVID-19 diagnosis, RCT design, minimum follow-up of 7 days, and minimum sample size of 100 subjects. For the recommendation on vaccination against COVID-19 (Recommendation 15), the additional criterion of retrospective cohort studies with at least 400 cases was also included.

VITT context experts initially proposed 8 “patient, intervention, comparator, outcome” (PICO) questions. Of these, 4 were excluded due to lack of evidence. For the remaining VITT-related PICOs, only nonrandomized studies on intervention effects were available. Producing recommendations for interventions based on nonrandomized studies is challenging because of the greater risk of bias compared with RCTs. Nonetheless, panelists agreed that because VITT is a rare disease, it was important to include all available evidence that met inclusion criteria for this condition.

Accordingly, prespecified criteria for inclusion of studies on VITT (laboratory diagnosis, heparin vs nonheparin, and intravenous gammaglobulin [IVIG]) were date range June 11, 2020, to August 03, 2023, human subjects of any age, established VITT (for treatment-related questions), suspected VITT (for diagnosis-related questions), cohort or case-control design, specification of a gold standard comparison for diagnostic accuracy studies, and minimum sample size of 30 subjects.

As with the original version of the guideline, results files for the vaccine/VITT literature searches were loaded into an online abstract review platform [7]. Two reviewers screened abstracts against the prespecified inclusion criteria, and the guideline methodologist adjudicated any conflicts that arose during abstract review. Full-text copies of potentially relevant studies were provided to members of the vaccine/ VITT working group. The working group, guideline Chairman, and methodologist reviewed all papers and together determined which met inclusion criteria.

Studies published after the literature search end dates and up to October 31, 2023, were eligible for inclusion if they met relevant criteria and had the potential to change the recommendations. Panel members did not become aware of any such studies after the close of the searches.

### 3.4 | Assessment of bias and the strength and quality of evidence

Evidence tables describing characteristics and outcomes of included studies are available in the online [Supplementary material](#). Development of written recommendations followed ACCF/AHA methods (Figure 1), with the COR indicating whether and to what degree panelists determined that available evidence reflects benefits or harms associated with a particular treatment and the LOE reflecting panelists' assessment of the quality of the studies that inform the recommendation. Only PICO questions represented by studies fulfilling LOE A or B were included in this guideline. Vaccine/VITT evidence table development and bias assessment followed the same methodology as the original version of the guidelines [4]. For the

PICO questions on treatment of VITT, the available studies only fulfilled LOE C-LD, but this information should be important for providers and patients. It is very unlikely that new studies with higher quality of evidence on treatment of VITT will become available, and therefore, the panel decided to include Recommendations 18 and 19 in the guidelines. In addition, for questions related to diagnostic accuracy of VITT, sensitivity, specificity, and positive predictive values (PPVs) and negative predictive values (NPVs) were calculated when data were available, and the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2) was used [9]. The latter method assesses 4 risk-of-bias domains in diagnostic accuracy studies, with each domain consisting of several questions. These domains are patient selection, index test, reference standard, flow, and timing. The first 3 domains are also assessed in terms of concerns regarding applicability. In assessing risk of bias for a given domain, if answers to all domain-specific questions are judged as “yes,” then risk of bias for that domain can be judged as low. If any questions are judged as “no,” then potential for bias exists. A similar approach applies for judgment of applicability, with reviewers rating how well the study matches the review question.

### 3.5 | Debate and voting

Each working group presented assessments of quality of evidence and strength of recommendations for the recommendations in its section. Panel members received section-specific materials in advance of virtual meetings; all could contribute to the discussion and prepare recommendations for voting. Panel discussions were recorded, and members had an opportunity to review the recordings and make additional comments. Discussions were aimed at reaching consensus among the panelists. Voting for all recommendations was conducted using a confidential ISTH website and was based on methods outlined by ACCF/AHA, with recusals as appropriate. Intellectual conflict of interest did not disqualify them from voting. Recommendations were approved by 94% to 100% of panel members, with at least 51% required for approval.

### 3.6 | Public review and comment

The final draft of these guidelines was posted on the ISTH website and made available for organizations with different stakeholders, including patients, for public review for 2 weeks, and comments were invited. The guideline Chairman reviewed all comments, consulted with the appropriate working group if needed, and responded. Recommendation-specific supportive texts were revised as required by the public comments.

## 4 | TREATMENT RECOMMENDATIONS

Each of the 5 sections starts with a tabular list of recommendations, each one with a brief comment below if the recommendation is new or

CLASS (STRENGTH) OF RECOMMENDATION	LEVEL (QUALITY) OF EVIDENCE‡
<b>CLASS 1 (STRONG)</b> <span style="float: right;">Benefit &gt;&gt;&gt; Risk</span> <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>Is recommended</li> <li>Is indicated/useful/effective/beneficial</li> <li>Should be performed/administered/other</li> <li>Comparative-Effectiveness Phrases†: <ul style="list-style-type: none"> <li>Treatment/strategy A is recommended/indicated in preference to treatment B</li> <li>Treatment A should be chosen over treatment B</li> </ul> </li> </ul>	<b>LEVEL A</b> <ul style="list-style-type: none"> <li>High-quality evidence‡ from more than 1 RCT</li> <li>Meta-analyses of high-quality RCTs</li> <li>One or more RCTs corroborated by high-quality registry studies</li> </ul>
<b>CLASS 2a (MODERATE)</b> <span style="float: right;">Benefit &gt;&gt; Risk</span> <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>Is reasonable</li> <li>Can be useful/effective/beneficial</li> <li>Comparative-Effectiveness Phrases†: <ul style="list-style-type: none"> <li>Treatment/strategy A is probably recommended/indicated in preference to treatment B</li> <li>It is reasonable to choose treatment A over treatment B</li> </ul> </li> </ul>	<b>LEVEL B-R</b> <span style="float: right;">(Randomized)</span> <ul style="list-style-type: none"> <li>Moderate-quality evidence‡ from 1 or more RCTs</li> <li>Meta-analyses of moderate-quality RCTs</li> </ul>
<b>CLASS 2b (WEAK)</b> <span style="float: right;">Benefit ≥ Risk</span> <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>May/might be reasonable</li> <li>May/might be considered</li> <li>Usefulness/effectiveness is unknown/unclear/uncertain or not well-established</li> </ul>	<b>LEVEL B-NR</b> <span style="float: right;">(Nonrandomized)</span> <ul style="list-style-type: none"> <li>Moderate-quality evidence‡ from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies</li> <li>Meta-analyses of such studies</li> </ul>
<b>CLASS 3: No Benefit (MODERATE)</b> <span style="float: right;">Benefit = Risk</span> <b>(Generally, LOE A or B use only)</b> <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>Is not recommended</li> <li>Is not indicated/useful/effective/beneficial</li> <li>Should not be performed/administered/other</li> </ul>	<b>LEVEL C-LD</b> <span style="float: right;">(Limited Data)</span> <ul style="list-style-type: none"> <li>Randomized or nonrandomized observational or registry studies with limitations of design or execution</li> <li>Meta-analyses of such studies</li> <li>Physiological or mechanistic studies in human subjects</li> </ul>
<b>Class 3: Harm (STRONG)</b> <span style="float: right;">Risk &gt; Benefit</span> <b>Suggested phrases for writing recommendations:</b> <ul style="list-style-type: none"> <li>Potentially harmful</li> <li>Causes harm</li> <li>Associated with excess morbidity/mortality</li> <li>Should not be performed/administered/other</li> </ul>	<b>LEVEL C-EO</b> <span style="float: right;">(Expert Opinion)</span> <ul style="list-style-type: none"> <li>Consensus of expert opinion based on clinical experience</li> </ul>

COR and LOE are determined independently (any COR may be paired with any LOE).

A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

\* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).

† For comparative-effectiveness recommendations (COR 1 and 2a; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

‡ The method of assessing quality is evolving, including the application of standardized, widely-used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.

COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.

FIGURE 1 Classification of recommendations and level of evidence. Reprinted with permission. Source: Greenberg et al. [8].

has been modified. Unchanged recommendations from the 2022 ISTH guidelines do not have any comment or recommendation-specific supportive text. The reader is referred for that to the respective section in the 2022 ISTH guidelines [4]. Thereafter follows a synopsis and recommendation-specific supportive texts. Sequencing of the list of those texts within the body of the article is aligned with the numbering of recommendations used in the tables.

Whenever the type of heparin was defined in a study as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH), this is specified in the text. In some studies, the type was either not defined or the results were provided with the UFH and LMWH together, which is referred to as “heparins” in the text. The prophylactic, intermediate, and therapeutic-dose levels of UFH, LMWH, and direct oral anticoagulants (DOACs) included in these guidelines were presented in Table 1 in the 2022 ISTH guidelines [4].

The definition of “noncritically ill” and “critically ill” varies between studies. We examined data for these patient categories as defined by the inclusion criteria in each study, and details are available in the accompanying evidence tables under “Study Characteristics.”

## 4.1 | Antithrombotic therapy for nonhospitalized patients (Table 1)

### 4.1.1 | Synopsis

The term “nonhospitalized” refers to patients with COVID-19, residing in the community and without recent hospitalization for COVID-19. The treatments evaluated in this section were evaluated for



TABLE 1 Recommendations for antithrombotic therapy for nonhospitalized patients.

COR	LOE	
3: No benefit	B-R	1. In nonhospitalized patients with symptomatic COVID-19, initiation of antiplatelet therapy is not effective to reduce risk of hospitalization, arterial or venous thromboembolism, or mortality [10].  MODIFIED: "thrombosis" was changed to "thromboembolism" (Section 3.1 in the 2022 ISTH COVID-19 Guideline).
3: No benefit	A	2. In nonhospitalized patients with symptomatic COVID-19, initiation of direct oral anticoagulant therapy is not effective to reduce risk of hospitalization, arterial or venous thromboembolism, or mortality [10–13].  MODIFIED: "thrombosis" was changed to "thromboembolism." New evidence was added, and LOE was updated from B-R to A (Section 3.1 in the 2022 ISTH COVID-19 Guideline).
2b	B-R	3. In nonhospitalized patients with COVID-19 at higher risk of disease progression, initiation of oral sulodexide therapy within 3 days of symptom onset may be considered to reduce risk of hospitalization [14].
3: No benefit	B-R	4. In nonhospitalized patients with symptomatic COVID-19, thromboprophylaxis with low-molecular-weight heparin is not effective to reduce the risk of disease progression [15,16].  NEW: New evidence has been published to support a LOE B-R recommendation.

Evidence from referenced studies that support recommendations is summarized in online Supplementary Evidence Tables S1–S4.

COR, class or recommendation; LOE, level of evidence.

outcomes such as thromboembolism, subsequent hospitalization, or mortality. Three new RCTs provided additional evidence to forego treatment with a DOAC to reduce the risk for adverse outcomes in this patient population. A new recommendation was generated as the result of 2 recent trials evaluating LMWH at a prophylactic dose in nonhospitalized patients, both with negative results. In the vast majority of patients with COVID-19 and mild-moderate symptoms, the incidence of thromboembolism, hospitalization, or death appears to be so low that no antithrombotic therapy is required unless indicated by other preexisting diseases.

The 2 studies enrolled 689 patients, and both were discontinued because of slow recruitment/futility. There was no significant difference between the treatment groups for the composite outcome of all-cause death and all-cause admission to hospital at 21 days after randomization [16], or any unplanned hospitalization and all-cause mortality within 30 days [15], or for the individual outcomes of hospitalization, thromboembolism, death, or major bleeding.

## 4.2 | Antithrombotic therapy for noncritically ill, hospitalized patients (Table 2)

### 4.1.2 | Recommendation-specific supportive text

2. Three additional RCTs have been published comparing prophylactic dose of the DOAC rivaroxaban with placebo [11,13] or usual care [12] for 14 to 35 days in nonhospitalized patients with suspected COVID-19 or a positive SARS-CoV-2 polymerase chain reaction test. Patients had risk factors for thrombosis and/or clinical deterioration. Risk of bias was generally low. There was no significant difference between treatment groups for composite outcomes—venous thromboembolism (VTE), need for mechanical ventilation, acute myocardial infarction, stroke, acute limb ischemia, and death not attributed to major injury [12], or major venous and arterial thrombotic events [13], or separately for thromboembolism, myocardial infarction, death, or bleeding. Together with the previously published RCT [10], these 4 studies with 3098 patients and consistently negative results justified a change of the LOE from B-R to A.
4. In 2 RCTs, a prophylactic dose of the LMWH enoxaparin was compared with usual care for 14 to 21 days in nonhospitalized patients with symptomatic COVID-19 and positive SARS-CoV-2 polymerase chain reaction test plus at least 1 risk factor for severe disease [16], or body temperature higher than 37.5 °C [15].

### 4.2.1 | Synopsis

Three new RCTs comparing therapeutic dose with intermediate or prophylactic dose LMWH have been published, but only 1 had adequate sample size to evaluate outcomes [30]. This together with a new meta-analysis [31] provided support for adding "reduced risk of death" to the outcomes listed in the recommendation for therapeutic-dose heparin LMWH or UFH. Two new RCTs evaluated intermediate dose LMWH versus other dose regimens [29,33]. The results were mixed with reduced incidence of thromboembolism in one and increased risk of bleeding in the other study. Together with the inconsistent results from previous observational studies and 1 RCT, there is no evidence to support use of intermediate-dose heparins in this setting. One new, large RCT added to the evidence from previous trials that antiplatelet agents do not reduce the risk for adverse outcomes in noncritically ill, hospitalized patients [36]. Another new, large RCT (FREEDOM COVID) compared the effect of therapeutic dose of the DOAC apixaban with therapeutic-dose LMWH and with prophylactic dose LMWH [30]. The results were similar for apixaban and therapeutic-dose LMWH, both demonstrating reduced mortality compared to prophylactic dose. Although this was not the primary

TABLE 2 Recommendations for antithrombotic therapy for noncritically ill, hospitalized patients.

COR	LOE	
1	B-NR	5. In noncritically ill patients hospitalized for COVID-19, low (prophylactic) dose LMWH or UFH is recommended in preference to no LMWH or UFH to reduce risk of thromboembolism and possibly death [17–23].
1	A	6. In select noncritically ill patients hospitalized for COVID-19, therapeutic-dose LMWH or UFH is beneficial in preference to low (prophylactic) or intermediate dose LMWH or UFH to reduce risk of thromboembolism, end-organ failure, and death [24–31].  MODIFIED: The outcome “death” was added because of new evidence (Section 3.2. in the 2022 ISTH COVID-19 Guideline).
3: No benefit	A	7. In noncritically ill patients hospitalized for COVID-19, intermediate-dose LMWH or UFH is not recommended in preference to low (prophylactic) dose LMWH or UFH to reduce risk of thromboembolism and other adverse outcomes [29,32,33].  MODIFIED: New evidence has been added. LOE was updated from B-R to A (Section 3.2. in the 2022 ISTH COVID-19 Guideline).
3: Harm	A	8. In noncritically ill patients hospitalized for COVID-19, add-on treatment with an antiplatelet agent is potentially harmful and should not be used [34–36].  MODIFIED: New information is included in the supportive text.
2b	B-R	9. In noncritically ill patients hospitalized for COVID-19, therapeutic-dose apixaban is not well established but might be considered to reduce end-organ failure and death [30].  MODIFIED: New evidence has been published about therapeutic-dose apixaban (Section 3.2. in the 2022 ISTH COVID-19 Guideline).

Evidence from referenced studies that support recommendations is summarized in online Supplementary Evidence Tables S5–S9.

COR, class or recommendation; LMWH, low-molecular-weight heparin; LOE, level of evidence; UFH, unfractionated heparin.

endpoint, it can be argued that death is a hard endpoint that is difficult to neglect. However, the results contradicted those of a smaller RCT (AntiCoagulaTion cORoNavirus) with a different DOAC (rivaroxaban). For this reason, the recommendation informs that it is “not well established.”

Lastly, a small RCT comparing prophylactic to intermediate doses of rivaroxaban versus enoxaparin in hospitalized, noncritically ill patients found superiority of the former using a composite of multiple efficacy and safety endpoints. The panel did not include it in this guideline as it had several methodological limitations [37]. One registry study in 1500 patients compared UFH with LMWH in hospitalized patients with COVID-19 using propensity score analysis [38]. The need for organ failure support and mortality were higher among those treated with UFH, but there was no information on the doses used with UFH and LMWH, and therefore the data are inconclusive and do not qualify for a recommendation.

#### 4.2.2 | Recommendation-specific supportive text

6. The FREEDOM COVID trial randomized 3398 noncritically ill patients with COVID-19 to prophylactic-dose enoxaparin, therapeutic-dose enoxaparin, or therapeutic-dose apixaban [30]. All-cause mortality occurred in 7.0% of patients treated with prophylactic-dose enoxaparin and 4.9% of patients treated with therapeutic-dose anticoagulation, and intubation was required in 8.4% vs 6.4% of

patients, respectively; both differences were statistically significant. Two smaller trials that randomized 159 [28] and 315 [29] noncritically ill hospitalized COVID-19 patients, respectively, to therapeutic versus low or intermediate dose LMWH suggested lack of benefit of therapeutic anticoagulation, but these findings were too imprecise for definitive conclusions. An updated meta-analysis of high-quality studies of hospitalized, noncritically ill patients with COVID-19 found that therapeutic-dose anticoagulation with UFH or LMWH reduced all-cause mortality and major thromboembolism compared with prophylactic or intermediate-dose heparins, without a significant difference in major bleeding [31]. The recommendation was therefore modified to include reduced mortality risk. An exploratory analysis of a large multiplatform adaptive randomized trial [39] found that therapeutic-dose heparins increased organ support-free days in hospitalized patients with COVID-19 who were not severely ill at presentation or had low body mass index [40].

7. The Standard versus High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID) trial randomized 311 noncritically ill patients with COVID-19 to tinzaparin at prophylactic (4500 IU), intermediate (100 IU/kg), or therapeutic (175 IU/kg) doses given once daily during hospitalization and followed by 7 days prophylaxis after discharge [29]. There was no significant difference among treatment groups for the composite outcome of a symptomatic thrombotic event, need for noninvasive or invasive ventilation, or death within 30 days, and there were no major bleeding events. The

trial was stopped early based on futility analysis. The COVID-19 and dose of anticoagulation (COVI-DOSE) trial randomized hospitalized patients with COVID-19 ( $n = 1005$ , 80.1% noncritically ill and 19.9% critically ill) to weight-adjusted intermediate dose or fixed-dose thromboprophylaxis with LMWH [33]. The observed rate of symptomatic VTE was lower than expected and occurred in 1.2% of patients in the weight-adjusted intermediate dose group versus 2.1% in the fixed-dose prophylaxis group. This difference was not statistically significant, but there was a significant, 2-fold increase in major bleeding in the weight-adjusted intermediate dose LMWH group. Taken together, these results do not support use of intermediate-dose LMWH in noncritically ill patients with COVID-19.

8. The Anti-Coronavirus Therapies trial used a multifactorial design to randomize 2119 patients to aspirin (100 mg/day) plus rivaroxaban (2.5 mg twice daily) or usual care (and to colchicine or usual care) [36]. There were no significant differences between the combined antithrombotic treatment and usual-care groups for the composite outcome of major thrombosis (myocardial infarction, stroke, acute limb ischemia, or pulmonary embolism), the need for high-flow oxygen, mechanical ventilation, death, or serious bleeding. The large Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial ( $n = 14\,892$ ) [35] and a third RCT [34] revealed no mortality benefit for aspirin or a P2Y<sub>12</sub> inhibitor, respectively, as add-on therapy among noncritically ill patients hospitalized for COVID-19. The RECOVERY trial indicated evidence of harm with significantly increased risk for major bleeding among patients on antiplatelet therapy [35]. A fourth RCT that compared interventions including aspirin, clopidogrel, low-dose rivaroxaban, atorvastatin, and omeprazole to standard care was not included in this guideline due to the complexity of the intervention and because 36% of patients in the control group received at least 1 antiplatelet agent [41]. However, among patients who are already on antiplatelet therapy with clear indications, good clinical practice suggests continuing antiplatelet therapy among patients hospitalized for COVID-19 [42].

9. The FREEDOM trial randomized 3398 noncritically ill patients hospitalized with COVID-19, 1:1:1 to prophylactic-dose enoxaparin (40 mg once daily), therapeutic-dose enoxaparin (1 mg/kg twice daily), or therapeutic-dose apixaban (5 mg twice daily) [30]. The primary outcome was a 30-day composite of all-cause mortality, requirement for intensive care unit (ICU)-level of care, systemic thromboembolism, or ischemic stroke assessed in the combined therapeutic-dose groups compared with the prophylactic-dose group. There was no significant difference in the primary outcome between the treatment groups. All-cause mortality was reduced significantly from 7.0% among patients treated with prophylactic-dose enoxaparin to 4.9% of patients treated with therapeutic-dose anticoagulation. Similar results were observed for apixaban and LMWH, and major bleeding was infrequent in all 3 groups. Furthermore, fewer patients who were treated with therapeutic-dose anticoagulation required intubation.

### 4.3 | Antithrombotic therapy for critically ill, hospitalized patients (Table 3)

#### 4.3.1 | Synopsis

With the current, less aggressive SARS-CoV-2 variants and with increasing immunity in the population from vaccination and previous COVID-19 episodes, the number of patients hospitalized for COVID-19 and requiring organ support has diminished. Persons without such immunity are still susceptible for severe COVID-19, and they occasionally require treatment in an ICU. Two new RCTs addressed the value of intermediate dose regimen of LMWH in critical care. One study demonstrated a reduction of new thromboembolism compared with standard prophylactic dose [45], whereas the other study showed a significant increase in bleeding with intermediate dose [33]. Likewise, the 3 new RCTs that compared therapeutic-dose heparins

TABLE 3 Recommendations for antithrombotic therapy for critically ill, hospitalized patients.

COR	LOE	
3: No benefit	A	10. In critically ill patients hospitalized for COVID-19, intermediate dose LMWH or UFH is not recommended over prophylactic dose LMWH or UFH to reduce risk of adverse events, including mortality [33,43–45].  MODIFIED: New studies have been added, and LOE has therefore been updated from B-R to A for mortality; “thromboembolism” has been removed due to discrepant results (Section 3.3. in the 2022 ISTH COVID-19 Guideline).
3: No benefit	A	11. In critically ill patients hospitalized for COVID-19, therapeutic-dose LMWH or UFH is not recommended over usual-care or prophylactic dose LMWH or UFH [25,28,39,45–47].  MODIFIED: New studies have been added, and LOE has therefore been updated from B-R to A (Section 3.3. in the 2022 ISTH COVID-19 Guideline).
3: No benefit	A	12. In critically ill patients hospitalized for COVID-19, add-on treatment with an antiplatelet agent to prophylactic dose LMWH/UFH, is not recommended to reduce adverse events [35,47–50].  MODIFIED: New studies have been added, and LOE has therefore been updated from B-R to A. There is overall limited evidence for reduced mortality balanced by increased risk of bleeding, and COR has therefore been updated from 2b to 3:NB (Section 3.3. in the 2022 ISTH COVID-19 Guideline).

Evidence from referenced studies that support recommendations is summarized in online Supplementary Evidence Tables S10–S12.

COR, class or recommendation; LMWH, low-molecular-weight heparin; LOE, level of evidence; UFH, unfractionated heparin.



with lower doses provided mixed results with reduction of thromboembolism in 2 trials [45,47] but increased severe and moderate bleeding [47]. The balance between efficacy and safety is obviously difficult in these very ill patients. Another RCT explored the transition of patients from noncritically ill to critically ill and enrolled from the subset of patients in the Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia RCT that had been allocated to treatment dose heparin [51]. The patients were then rerandomized to continued treatment dose or to intermediate or standard prophylactic-dose heparin in the ICU. The therapeutic-dose arm was prematurely discontinued by the data safety monitoring board when 75 patients had been randomized for futility to demonstrate any advantage of continuing therapeutic-dose heparin. This small study did not qualify for a recommendation in the guideline.

Two new RCTs compared platelet inhibition with clopidogrel or ticagrelor versus usual care, and there was no evidence of efficacy benefit [47,49]. In the 2022 ISTH guidelines, the addition of antiplatelet agent to prophylactic dose heparin was given a very guarded positive suggestion, but with all 4 RCT results taken together, there is no support for a net benefit.

#### 4.3.2 | Recommendation-specific supportive text

10. The COVI-DOSE study was a multicenter, open-label, phase 4, superiority trial with blinded outcome adjudication that randomized 1000 adult inpatients presenting with acute respiratory SARS-CoV-2 into 2 treatment groups: intermediate weight-adjusted prophylactic dose LMWH or a fixed-dose of subcutaneous LMWH [33]. The observed rate of thromboembolic events was lower than expected in both groups. There was a statistically significant, 2-fold increased risk of major or clinically relevant nonmajor bleeding in the weight-adjusted dose group compared with the fixed-dose group, and no significant difference in thromboembolism or mortality. Similar in design to COVI-DOSE, the Anticoagulation COVID-19 study randomized 339 patients with hypoxemic COVID-19 pneumonia, of whom 90% were in an ICU at randomization [45]. Patients were assigned in equal numbers to standard prophylactic dose, high prophylactic dose, or treatment dose LMWH. Compared with standard prophylactic dose, neither high prophylactic dose nor treatment dose heparin improved the primary outcome of all-cause mortality or time to clinical improvement; however, the high prophylactic dose resulted in significantly better net clinical outcome by decreasing the risk of venous or arterial thrombosis without increased risk of bleeding. Taken together with 2 previous trials with negative findings [43,44], these results do not suggest any advantage of intermediate or high prophylactic dose LMWH compared with standard-dose LMWH among critically ill patients. A variety of factors may have contributed to the differences in outcome in the critically ill compared with the noncritically ill patients. Great variability in exposure to LMWH has been demonstrated in critically ill patients [52], but there is no evidence yet to support that adjustment of dose according to Xa-monitoring will lead to improved clinical outcomes.
11. The Anticoagulation COVID-19 randomized, open-label trial assigned equally 339 patients with hypoxemic COVID-19 pneumonia requiring supplemental oxygen to therapeutic anticoagulation or high-dose prophylactic anticoagulation with standard-dose prophylactic LMWH and with 90% of the patients in an ICU at randomization [45]. Compared with standard prophylactic dose, neither high prophylactic dose nor treatment dose heparin improved the primary hierarchical outcome of all-cause mortality or time to clinical improvement in patients with hypoxemic COVID-19 pneumonia; however, the high prophylactic dose resulted in significantly better net clinical outcome by decreasing the risk of venous or arterial thrombosis without increased risk of bleeding. In the Prevention of Arteriovenous Thrombotic Events in Critically-ill COVID-19 Patients Trial study, patients were randomized to full-dose anticoagulation or standard-dose prophylactic anticoagulation ( $n = 390$ ) [47], and patients with no indication for antiplatelet therapy were randomized to either clopidogrel or no antiplatelet therapy ( $n = 292$ ). In critically ill patients with COVID-19, full-dose anticoagulation, but not clopidogrel, significantly reduced thrombotic complications but with an increase in severe or moderate bleeding (Global Use of Strategies to Open Occluded Arteries definition) [53] that was driven primarily by transfusions in hemodynamically stable patients. No difference in mortality was observed between groups. In the smaller COVID-HEP trial, 159 patients with acute severe COVID-19 were randomized within 48 hours of hospital admission to therapeutic-dose LMWH or UFH versus intermediate or prophylactic dose LMWH or UFH [28]. However, only 88 patients were in the ICU, and there were no differences in thromboembolism, mortality, or major bleeding between groups. Taken together with the large, negative, multiplatform RCT (REMAP-CAP, Accelerating COVID-19 Therapeutic Interventions and Vaccines-4 Antithrombotics Inpatient, and Antithrombotic Therapy to Ameliorate Complications of COVID-19) [39] and the secondary analysis, which showed that heparin was more likely to cause harm in the more severely ill patients [40], the results of these trials do not suggest any advantage of therapeutic-dose heparin compared with lower doses among critically ill patients.
12. In the ACTIV-4a trial, which included 943 critically ill participants hospitalized for COVID-19, 14-day treatment with a P2Y<sub>12</sub> inhibitor compared with usual care did not improve the number of days alive and free of cardiovascular or respiratory organ support nor did it increase risk of major bleeding [49]. In the Prevention of Arteriovenous Thrombotic Events in Critically-ill COVID-19 Patients Trial multifactorial RCT, 290 critically ill patients with COVID-19 were randomized to clopidogrel versus usual care until hospital discharge or day 28 [47]. There were no significant differences in efficacy outcomes or bleeding between the 2 groups. Updated data of the REMAP-CAP trial have been

published with follow-up through 180 days for 895 patients in the platelet domain (initial publication was up to 90 days) [50]. Among critically ill patients with COVID-19 in this study who were randomized to receive one or more therapeutic interventions, treatment with an antiplatelet had a 95.0% probability of improved 180-day mortality compared with control; the posterior probability of superiority was not statistically significant. Taken together with negative findings from the RECOVERY trial, these data do not support routine use of an antiplatelet agent, and specifically not a P2Y12 inhibitor, in critically ill patients hospitalized for COVID-19. For patients who are already on an antiplatelet agent with clear indications, good clinical practice suggests continuation of antiplatelet therapy if a patient is hospitalized for COVID-19 [42].

#### 4.4 | Antithrombotic therapy for patients discharged from hospital (Table 4)

##### 4.4.1 | Synopsis

In the 2022 ISTH guidelines [4], a single RCT was available for evaluating postdischarge prophylaxis—rivaroxaban for 30 days—reducing the risk for thromboembolism in the Medically Ill hospitalized patients for Covid -19 tHrombosis Extended prophylaxis with rivaroxaban thErapy trial [56]. Since then, another RCT (ACTIV-4C) compared prophylactic dose apixaban vs placebo without any apparent differences between the groups [54]. The study was stopped for low event rate and declining accrual rate. An important difference between the 2 studies is the selected high-risk population in the Medically Ill hospitalized patients for Covid -19 tHrombosis Extended prophylaxis with rivaroxaban thErapy trial versus the broad patient population in ACTIV-4C. Although the ACTIV-4C was inconclusive, together with data from a number of observational studies (Table 5), it demonstrated that the adverse event rate after discharge is declining and currently so low that for the vast majority of patients, there is no benefit from postdischarge prophylaxis with anticoagulants. A small subset of patients at high risk

for thromboembolism, based on previous medical history, elevated D-dimer, or a high score in the International Medical Prevention Registry on Venous Thromboembolism risk assessment model [60], should still be considered for postdischarge prophylaxis. The recommendation was therefore split in 2: the first for patients in general with no need for prophylaxis, and the second for a highly selected subset of patients at high risk for thromboembolism to consider rivaroxaban at a dose of 10 mg daily.

##### 4.4.2 | Recommendation-specific supportive text

13. The ACTIV-4c randomized, double-blind trial compared apixaban at a prophylactic dose (2.5 mg twice daily) with placebo for 30 days in 1217 patients discharged after hospitalization for COVID-19 [54]. Recruitment spanned the period of February 2021 to June 2022, covering the Delta and early Omicron variant waves. Both event and recruitment rates were lower than expected, prompting early discontinuation of the trial. Due to low incidence of the composite endpoint of death or any thromboembolism (apixaban 2.1%, placebo 2.3%), results were imprecise. In an observational study using linked databases, rates of serious clinical outcomes in 77 347 patients discharged after hospitalization for COVID-19 during 2020-2021 were compared with those of patients discharged after prepandemic pneumonia and with controls [61]. The risk of deep vein thrombosis during the following 5 months was comparable for COVID-19 and non-COVID pneumonia, and risk for pulmonary embolism was slightly higher for COVID-19. The trend of decreasing risk of thromboembolism or death among patients without thromboprophylaxis postdischarge is shown in Table 5. Routine postdischarge thromboprophylaxis is not recommended for patients hospitalized for non-COVID pneumonia.
14. As the incidence of thromboembolic events in postdischarge patients has decreased since the onset of COVID-19 pandemic, need for postdischarge prophylactic anticoagulation is reduced and should be reserved for those at highest risk [56].

TABLE 4 Recommendation for patients discharged from hospital.

COR	LOE	
3: No benefit	A	13. In patients who have been hospitalized for COVID-19 and are not deemed at high risk for complications, routine postdischarge prophylactic dose direct oral anticoagulant is not recommended to reduce the risk of death or thromboembolism [54].  NEW: A new randomized controlled trial, together with observational studies demonstrating a trend in decreasing severity of COVID-19, supports a LOE A recommendation (Section 3.4. in the 2022 ISTH COVID-19 Guideline).
2b	B-R	14. In select high-risk patients who have been hospitalized for COVID-19, postdischarge treatment with prophylactic-dose rivaroxaban for approximately 30 days may be considered to reduce risk of major thromboembolism [55,56].  MODIFIED: "high-risk" has been added to point out the difference from recommendation 13 (Section 3.4. in the 2022 ISTH COVID-19 Guideline).

Evidence from referenced studies that support recommendations is summarized in online Supplementary Evidence Tables S13 and S14.

COR, class or recommendation; LOE, level of evidence.

TABLE 5 Rates of thromboembolism and death without thromboprophylaxis during different periods of the COVID-19 pandemic.

Author	Study type	Study period	Follow-up	N	VTE, %	ATE, %	Death, %
Giannis et al. [55] <sup>a</sup>	Registry	March to May 2020	3 months	4313	1.55	1.72	4.83
Courtney et al. [57]	Observational	March to October 2020	35 days	1039	1.3	–	–
Li et al. [58] <sup>b</sup>	Observational	March to November 2020	3 months	2116	1.6	0.5	3.8
Arachchillage et al. [59]	Observational	April 2020 to December 2021	3 months	971	0.9	–	–
Wang et al. [54]	Randomized controlled trial	February 2021 to June 2022	30 days <sup>c</sup>	607	0.82	0.49	1.48

ATE, arterial thromboembolism; VTE, venous thromboembolism.

<sup>a</sup> Eighty-nine percent did not receive prophylaxis.

<sup>b</sup> The result for VTE is in patients without postdischarge anticoagulation (76% of the entire population), whereas results for ATE and death are for the whole study population.

<sup>c</sup> The primary outcome was the event rate at 30 days. By 3 months, the composite outcome of thromboembolism and death had increased from 2.3% to 2.8%.

## 4.5 | COVID-19 vaccination and VITT (Table 6) (New)

### 4.5.1 | Synopsis (New)

There has been substantial hesitance and even resistance against COVID-19 vaccination in many populations, partly fueled by the occurrence of very rare side effects, including VITT and myocarditis. VITT was recognized as a new syndrome following the use of adenoviral vector-based vaccines for COVID-19. Because of the similarities between VITT and severe forms of heparin-induced thrombocytopenia (HIT), treatments that are used to treat severe HIT and prevent thromboembolism were adopted for VITT, including anticoagulants and IVIG.

We acknowledge that the AHA rubric that is being applied to evaluate the level (quality) of evidence was not designed for the evaluation of diagnostic tests. The use of VITT-associated vaccines has diminished in high-income countries; however, VITT continues to be an important consideration for low-to-middle-income

countries and remains an issue of health equity [72]. Important knowledge gaps remain, and there is an ongoing need for additional research, including comparison of multiple assays to clarify the optimal diagnostic approach. Where resources to perform these assays are unavailable, the diagnosis of VITT can be established based on a high degree of suspicion (eg, probable VITT), defined as a high D-dimer and thrombocytopenia (<150 000/μL) and thrombosis occurring 5-30 days after vaccination with adenoviral vector-based vaccine for COVID-19.

Patients with a history of thromboembolism have been naturally concerned about the risk of recurrent thrombosis after vaccination. A large observational study in patients with a diagnosed thrombophilia defect did not show increased risk for thrombosis during 3 months after almost exclusive use of the messenger RNA vaccines [62].

The treatment of VITT is complex, which makes the interpretation of studies that focus on a single agent challenging. Furthermore, as information about VITT rapidly accumulated, the diagnosis was made sooner, and the management of the disease changed. There is thus important confounding in the studies on treatment of VITT. The use of

TABLE 6 Recommendation for patients with COVID-19 vaccination or with vaccine-induced immune thrombotic thrombocytopenia.

COR	LOE	
3: No benefit	B-NR	15. For nonhospitalized patients with thrombophilia who receive a COVID-19 vaccine, prophylaxis with anticoagulants or an antiplatelet agent is not recommended for reducing risk of adverse outcomes [62].
1	B-NR	16. For diagnosing patients with suspected VITT, use of antiplatelet factor 4 enzyme immunoassays is recommended [58,63–67].
3: No benefit	B-NR	17. For diagnosing patients with suspected VITT, use of rapid heparin-induced thrombocytopenia assays such as particle gel immunoassay, lateral-flow assay, latex-enhanced immunoturbidimetric assay, or chemiluminescence immunoassay is not recommended [67].
2a	C-LD	18. For patients with VITT, when a nonheparin anticoagulant is unavailable, treatment with UFH or LMWH is reasonable for reducing risk of adverse outcomes [68–71].
2b	C-LD	19. For patients with VITT, treatment with intravenous immune globulin may be considered for reducing risk of death [69–71].

Evidence from referenced studies that support recommendations is summarized in online Supplementary Evidence Tables S15–S19.

COR, class or recommendation; LMWH, low-molecular-weight heparin; LOE, level of evidence; UFH, unfractionated; VITT, vaccine-induced immune thrombotic thrombocytopenia.

heparins to treat the thrombotic events in VITT was of potential concern due to similarities between VITT and HIT. In countries with limited resources, the more expensive nonheparin anticoagulants are not available. The panel identified 3 studies comparing heparins with nonheparin agents [69–71] and 1 meta-analysis [68] that rendered support for the safe use of heparins, although nonheparin anticoagulants might still be preferred.

For the use of IVIG, 3 studies with more than 30 patients were identified, with 2 demonstrating reduced mortality compared with usual care [70,71], whereas the largest study did not find a difference [69]. Therefore, only weak support for the use of IVIG was given in the recommendation.

#### 4.5.2 | Recommendation-specific supportive text (New)

15. Based on electronic medical records across the Mayo Clinic enterprise, a cohort study of 6067 adults with inherited or acquired thrombophilia who were vaccinated for COVID-19 examined acute VTE occurrence in the 90 days before and after the first vaccine dose [62]. There were 51 and 39 VTE events before and after vaccination, with no statistically significant difference. No differences were found when the data were analyzed by thrombophilia type (ie, factor V Leiden prothrombin gene mutation or antiphospholipid syndrome). No data were presented on the proportion of patients on antithrombotic treatment. The annualized thrombotic event rate during the 90 days before vaccination was 3.3%, which can be compared with literature data. Systematic reviews and meta-analyses, including studies of patients with unprovoked VTE with a high risk of recurrence (similar to those with thrombophilia and VTE), have shown that with long-term anticoagulation the incidence of VTE recurrence is 1.4% per year [73], and after stopping anticoagulation, VTE recurrence is 3.6% per year [74]. Data from this cohort study suggest that the

majority of patients were not on anticoagulation at the time of VTE recurrence or vaccination.

16. Six studies were eligible for evaluation of performance characteristics [63–67,75]. Anti-platelet factor 4 (PF4) enzyme immunoassays (EIA) have excellent diagnostic accuracy for the diagnosis of VITT. Prevalence impacts both NPV and PPV. Based on eligible studies, median NPV of EIA is 1.0 (range, 0.76, 1.0), and median PPV of EIA is 0.86 (range, 0.51, 1.0) (see Table 7). Therefore, a negative EIA essentially rules out the diagnosis of VITT unless high clinical suspicion remains [64]. In cases where there is high clinical suspicion of VITT and EIA testing is negative, testing using another EIA assay and VITT-modified functional testing for PF4-related platelet activation is suggested. A positive EIA correlates well with the presence of PF4-platelet activating antibodies [63,65–67,75]; thus, a positive EIA essentially rules in VITT when there is substantial clinical suspicion.

17. Only one cohort study of 34 patients with suspected VITT was eligible for inclusion [67]. A rapid assay for HIT, particle gel immunoassay, was compared with a modified heparin-induced platelet aggregation assay as the reference standard. Sensitivity, specificity, PPV, and NPV for particle gel immunoassay were 0.54, 0.67, 0.54, and 0.61, respectively. Despite limited evidence comparing rapid HIT assays to the gold standard (VITT-modified functional testing for PF4-related platelet activation), indirect evidence demonstrating poor correlation between rapid HIT assay and EIA results supports the recommendation against the use of rapid HIT assays for VITT diagnosis. Rapid HIT assays are not sensitive for VITT and are likely to yield false negative results [67]. VITT antibodies bind to PF4 alone with variable reactivity against the PF4-heparin complex. The reduced sensitivity of the rapid assays for VITT compared with HIT may be due to competition between heparin and VITT antibodies for the heparin-binding site on PF4 or the lack of competition between KKO (a mouse monoclonal that

**TABLE 7** Performance characteristics of enzyme immunoassays for vaccine-induced immune thrombotic thrombocytopenia.

Author	EIA test	Sensitivity	Specificity	NPV	PPV
Bissola et al. [63]	Lifecodes: IgG/A/M-EIA	1.0	0.96	1.0	0.90
	In-house: PF4 EIA	1.0	0.97	1.0	0.92
	In-house: PF4/heparin-EIA	1.0	0.97	1.0	0.94
Mouta Nunes de Oliveira et al. [65]	PF4/heparin IgG ELISA	1.0	1.0	1.0	1.0
Favaloro et al. [64]	Asserachrom HPIA IgG ELISA	0.67	0.82	0.76	0.74
		0.64	0.76	0.82	0.55
		0.85	0.65	0.91	0.51
Lee et al. [75]	PF4/heparin IgG ELISA	1.0	0.83	1.0	0.85
Thiele et al. [66]	Anti-PF4/heparin IgG ELISA	1.0	0.80	1.0	0.95
Uzun et al. [67]	Zymutest HIA IgG	1.0	0.87	1.0	0.90

Anti-PF4, antiplatelet factor 4; EIA, enzyme immunoassay; HIA, heparin induced antibodies; HPIA, heparin platelet induced antibodies; IgG, immunoglobulin G; NPV, negative predictive value; PPV, positive predictive value.

resembles HIT antibodies) and VITT antibodies, which is essential for proper assay functioning in the case of latex-enhanced immunoturbidimetric assay. Thus, rapid HIT assays are not useful for VITT diagnosis and are potentially harmful when used as a stand-alone diagnostic test for VITT because they may delay initiation of treatment for this life-threatening condition. However, the evidence for harm is indirect and of low quality in the absence of reliable clinical data.

18. An international prospective registry of patients with definite VITT and cerebral vein thrombosis compared treatment with nonheparin anticoagulants ( $n = 51$ ) with heparin ( $n = 35$ ) [71]. There was no difference in mortality or new VTE between groups. In a prospective cohort study of 170 cases of definite VITT and 50 cases of probable VITT, 150 patients were treated with nonheparin anticoagulants, and 50 received a heparin at some point during their hospital admission [69]. Mortality was numerically higher in patients who received heparin, but the difference was not statistically significant. In a multicenter, retrospective analysis of patients with cerebral venous thrombosis and definite or probable VITT, data on clinical characteristics, laboratory results, treatments, and outcomes were collected [70]. Death or dependence (modified Rankin score 3-6) occurred in 8 of 16 treated with UFH or LMWH, in 18 of 50 with a nonheparin anticoagulant and 4 of 22 treated with a DOAC, with none of the differences being statistically significant. A meta-analysis including 2 of the above-mentioned studies [69,70] and an additional study showed no difference in mortality between patients treated with heparin and those receiving a nonheparin anticoagulant (19% vs 17%) [68]. Given the small number of total patients, nonrandomized use of anticoagulants, confounding by use of other treatments, and change in mortality over time with the evolution in understanding and treatment of VITT, use of a heparin anticoagulant is reasonable if nonheparin anticoagulants are unavailable.
19. An international prospective registry of patients with definite VITT and cerebral vein thrombosis compared treatment with immunomodulation ( $n = 65$ ) with no immunomodulation ( $n = 34$ ) [71]. Immunomodulation was used in 94% of cases with IVIG. Mortality was significantly lower with immunomodulation, but there was no difference in risk of new VTE between the treatment groups. In a prospective cohort study of 170 cases of definite VITT and 50 cases of probable VITT, 159 were treated with IVIG, and 61 were not; overall, 72% of these 220 patients were treated with IVIG [69]. Mortality was similar in the 2 groups. In a multicenter, retrospective analysis of patients with cerebral venous thrombosis and VITT, data on clinical characteristics, laboratory results, treatments, and outcomes were collected [70]. Death or dependence (modified Rankin score 3-6) occurred in 22 of 55 treated with IVIG and in 11 of 15 not treated with IVIG. Although authors of some of these studies noted that patients treated with IVIG had a trend toward fewer deaths compared with those not treated with IVIG, sample sizes were too small for robust comparisons. Based on the small number of patients, nonrandomized administration of IVIG, and confounding by simultaneous use of

anticoagulation, use of high-dose IVIG may be considered in the treatment of VITT.

## 5 | DISCUSSION

During the 4 years of the COVID-19 pandemic, the disease panorama has changed substantially due to the emergence of new, dominant virus variants with differences in transmissibility and severity of disease and improved herd immunity. Many patients are now hospitalized for other reasons and have concomitant COVID-19 or contract it during the hospitalization. Our recommendations may not be generalizable for such cases since the studies mainly included patients hospitalized for COVID-19. Although more than 16 new RCTs on antithrombotic treatment for patients with COVID-19 were published since the 2022 ISTH guidelines, it is important to note that several of them were discontinued prematurely due to accrual problems. Nevertheless, the totality of evidence rendered support for an upgrade of LOE for 5 recommendations. Two recommendations were added for the nonhospitalized and postdischarge patients. For the vaccine and VITT section of the initially raised questions, 2 were combined (anticoagulation prophylaxis for patients with thrombophilia and antiplatelet prophylaxis for the same group), 1 was considered already answered (anticoagulation prophylaxis for the general population since not needed in persons with thrombophilia), and 2 had insufficient or low-quality evidence (use of plasma exchange, rituximab or other agents for severe VITT, or subsequent messenger RNA vaccine for patients who had VITT). Any of these questions might be addressed in a future ISTH Guidance document. Two recommendations discuss use of specific DOACs (recommendation 9 – apixaban and recommendation 14 – rivaroxaban), as no data for other DOACs were available demonstrating a favorable risk/benefit ratio for the respective indication. Differences in properties between DOACs, such as protein binding, metabolism, renal elimination, drug interactions, dosing regimens, and possibly bleeding risk, preclude generalization of these recommendations to include all DOACs. As opposed to the 2022 ISTH guidelines, there are no accompanying Good Practice Statements since very little has changed in that part.

## 6 | CONCLUSION

The treatment recommendations for COVID-19 are summarized in Figure 2. The recommendations for vaccination and VITT are summarized in Figure 3.


## ACKNOWLEDGMENTS

This work was supported by ISTH. The authors are grateful for the administrative support provided by Andrea Hickman and Cary Clark.

## AUTHOR CONTRIBUTIONS

S.S. planned and organized the guideline work; H.R. led the literature search, created the evidence tables for the vaccine and VITT section,





**FIGURE 2** Summary of recommendations 1 to 14 on symptomatic COVID-19. Color coding refers to the class of recommendation (COR). For further details, see recommendation-specific supportive texts and evidence tables (in [Supplementary Table S1](#)). DOAC, direct oral anticoagulant; LMWH, low-molecular-weight heparin; LOE, level of evidence; UFH, unfractionated heparin.


and provided methodological guidance. All authors analyzed the data and contributed to the text and tables.

#### DECLARATION OF COMPETING INTERESTS

S.S. has received a research grant from Octapharma; served on data safety monitoring boards for Alexion, Bayer, Boehringer-Ingelheim, and Sanofi; served on event adjudication for Daiichi Sankyo; and served on an advisory board for Servier. D.M.A. received research grants from Rigel Pharmaceuticals and the Public Health Agency of Canada and is a consultant for Amgen, Paradigm, Sobi, Alpine, Novartis, and Argenx. C.A.B. has received a research grant from Amgen, honoraria from BMS-Pfizer, Janssen, and Sanofi, and served on the advisory board for Novartis. L.B. currently owns a stock portfolio with Johnson & Johnson and Pfizer. J.M.C. has received a research grant from CSL Behring and has served on scientific advisory boards for Abbott, Anthos, Bristol Myers Squibb, Pfizer, and Werfen. A.F. has received honoraria from Kedrion and Rovi and served on an advisory board for Sanofi. S.K. has received research grants from Bayer and is a consultant for Inari and Janssen. J.H.L. has served on a data safety monitoring board with Merck, a research study steering committee with Octapharma, and the advisory board for Werfen. S.M. has received research grants from Bayer, Abbvie, Hemab, Viartis, and Sanofi and honoraria from AstraZeneca, Norgine, and Alveron. I.N. has received research grants from Paradigm Pharmaceuticals, Janssen/Johnson & Johnson, UCB Biopharma, AstraZeneca, and the Public Health Agency of Canada and is a consultant for Paradigm Pharmaceuticals, Janssen/Johnson & Johnson, UCB Biopharma, and AstraZeneca. E.R. has received research grants

from Bayer, Pfizer, and Novartis and honoraria from Sanofi, Bayer, Ache, Daiichi Sankyo, and Pfizer. C.M.S. served on an advisory board for Norgine Pharma. M.S. has received research grants from Pfizer, Amgen, and Sanofi; received honoraria from Pfizer, Octapharma, Amgen, and Novartis; and served on advisory boards for Amgen and Novartis. A.C.S. has received a research grant from AstraZeneca and honoraria from Janssen, Regeneron, and AstraZeneca. J.T. received honoraria from Bristol Myers Squibb, Pfizer, and Daiichi Sankyo. R.Z. has received research grants from the Canadian Institute of Health Research, Life-Arc, Nation Institute of Health, Research Manitoba, CancerCare Manitoba Foundation, Peter Munk Cardiac Centre, Thistledown Foundation, and Manitoba Medical Services Foundation. The remaining authors have no conflicts of interest to declare.

S.S. has been primary author and coauthor on review articles on COVID-19. D.M.A. has been coauthor and senior author on articles on diagnosis and treatment of VITT. C.A.B. has been primary author and co-author on articles on heparins and antiplatelet agents for treatment of COVID-19. J.M.C. has been primary author and coauthor on articles on antiplatelet agents, apixaban, and heparin for treatment of COVID-19. A.F. has been coauthor on review articles on treatment of COVID-19, including with heparin. T.I. has been primary author and coauthor on articles on coagulopathy in COVID-19 and in VITT. S.K. has been coauthor on articles on heparin and antiplatelet agents for treatment of COVID-19. J.H.L. has been primary author and coauthor on articles on coagulopathy in COVID-19 and in VITT and on heparin for treatment of COVID-19. S.M. has been coauthor on articles on heparin and oral anticoagulants for the treatment of COVID-19. I.N.



**FIGURE 3** Summary of recommendations 15 to 19 on vaccination and vaccine-induced immune thrombotic thrombocytopenia (VITT). Color coding refers to the class of recommendation (COR). For further details, see recommendation-specific supportive texts and evidence tables (in [Supplementary Table S1](#)). HIT, heparin-induced thrombocytopenia; LMWH, low-molecular-weight heparin; LOE, level of evidence; UFH, unfractionated heparin.

has been primary author, senior author, and coauthor on articles on coagulopathy and laboratory diagnosis in VITT and COVID-19. C.M.S. has been coauthor on articles on coagulopathy in COVID-19. M.S. has been primary author on articles on heparin for treatment of COVID-19. A.C.S. has been primary author and senior author on articles on heparin and coauthor on articles on rivaroxaban for treatment of COVID-19. J.T. has been primary author and coauthor on articles on coagulopathy in COVID-19. R.Z. has been primary author and coauthor on articles on heparin and antiplatelet agents, respectively, for treatment of COVID-19. The remaining authors have no intellectual conflicts of interest.

#### ORCID

Sam Schulman <https://orcid.org/0000-0002-8512-9043>

#### REFERENCES

- [1] Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. *Acta Biomed*. 2020;91:157–60.
- [2] The Center for Systems Science and Engineering at the Department of Civil and Systems Engineering at Johns Hopkins University. COVID-19 Dashboard. <https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6>; 2023 [accessed November 20, 2023].
- [3] Holder J. *Tracking coronavirus vaccinations around the world*. The New York Times; 2023.
- [4] Schulman S, Sholzberg M, Spyropoulos AC, Zarychanski R, Resnick HE, Bradbury CA, Broxmeyer L, Connors JM, Falanga A, Iba T, Kaatz S, Levy JH, Middeldorp S, Minichiello T, Ramacciotti E, Samama CM, Thachil J, International Society on Thrombosis and Haemostasis. ISTH guidelines for antithrombotic treatment in COVID-19. *J Thromb Haemost*. 2022;20:2214–25.
- [5] Jacobs AK, Kushner FG, Ettinger SM, Guyton RA, Anderson JL, Ohman EM, Albert NM, Antman EM, Arnett DK, Bertot M, Bhatt DL, Brindis RG, Creager MA, DeMets DL, Dickersin K, Fonarow GC, Gibbons RJ, Halperin JL, Hochman JS, Koster MA, et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;127:268–310.
- [6] American College of Cardiology Foundation and American Heart Association. Methodology manual and policies from the ACCF/AHA Task Force on Practice Guidelines. <https://www.acc.org/-/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Guidelines/About-Guidelines-and-Clinical-Documents/Methodology/2014/Methodology-Practice-Guidelines.pdf?la=en&hash=CBE36C37EF806E7C7B193DD4450C5D190DEBB5E3>; 2010 [accessed March 17, 2022].
- [7] Brown University, School of Public Health. Abstrackr. <https://www.brown.edu/public-health/cesh/resources/software/#:~:text=using%20these%20tools,-Abstrackr,your%20abstracts%20in%20one%20place>; 2023 [accessed November 20, 2023].

- [8] Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, Hemphill JC 3rd, Johnson R, Keigher KM, Mack WJ, Mocco J, Newton EJ, Ruff IM, Sansing LH, Schulman S, Selim MH, Sheth KN, Sprigg N, Sunnerhagen KS. American Heart Association/American Stroke Association. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. *Stroke*. 2022;53:e282–361.
- [9] Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med*. 2011;155:529–36.
- [10] Connors JM, Brooks MM, Sciruba FC, Krishnan JA, Bledsoe JR, Kindzelski A, Baucom AL, Kirwan BA, Eng H, Martin D, Zaharris E, Everett B, Castro L, Shapiro NL, Lin JY, Hou PC, Pepine CJ, Handberg E, Haight DO, Wilson JW, et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. *JAMA*. 2021;326:1703–12.
- [11] Ananworanich J, Mogg R, Dunne MW, Bassyouni M, David CV, Gonzalez E, Rogalski-Salter T, Shih H, Silverman J, Medema J, Heaton P. Randomized study of rivaroxaban vs placebo on disease progression and symptoms resolution in high-risk adults with mild coronavirus disease 2019. *Clin Infect Dis*. 2022;75:e473–81.
- [12] Avezum Á, Oliveira Junior HA, Neves PDMM, Alves LBO, Calvacanti AB, Rosa RG, Veiga VC, Azevedo LCP, Zimmermann SL, Silvestre OM, Seabra Prudente RC, Morales Kormann AP, Moreira FR, Boszczowski I, de Brito Sobrinho E, da Silva E Souza A, Seligman R, de Souza Paolino B, Razuk A, Diogenes de Magalhães Feitosa A, et al. Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE - COALITION VIII randomised clinical trial. *EClinicalMedicine*. 2023;60:102004.
- [13] Piazza G, Spyropoulos AC, Hsia J, Goldin M, Towner WJ, Go AS, Bull TM, Weng S, Lipardi C, Barnathan ES, Bonaca MP, PREVENT-HD Investigators. Rivaroxaban for prevention of thrombotic events, hospitalization, and death in outpatients with COVID-19: a randomized clinical trial. *Circulation*. 2023;147:1891–901.
- [14] Gonzalez-Ochoa AJ, Raffetto JD, Hernández AG, Zavala N, Gutiérrez O, Vargas A, Loustaunau J. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. *Thromb Haemost*. 2021;121:944–54.
- [15] Barco S, Voci D, Held U, Sebastian T, Bingisser R, Colucci G, Duerschmied D, Frenk A, Gerber B, Götschi A, Konstantinides SV, Mach F, Robert-Ebadi H, Rosemann T, Simon NR, Spechbach H, Spirk D, Stortecky S, Vaisnora L, Righini M, et al. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet Haematol*. 2022;9:e585–93.
- [16] Cools F, Virdone S, Sawhney J, Lopes RD, Jacobson B, Arcelus JI, Hobbs FDR, Gibbs H, Himmelreich JCL, MacCallum P, Schellong S, Haas S, Turpie AGG, Ageno W, Rocha AT, Kayani G, Pieper K, Kakkar AK, ETHIC investigators. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. *Lancet Haematol*. 2022;9:e594–604.
- [17] Battistoni I, Francioni M, Morici N, Rubboli A, Podda GM, Pappalardo A, Abdelrahim MEA, Elgendy MO, Elgendy SO, Khalaf AM, Hamied AAM, Garcés HH, Abdelhamid OES, Tawfik KAM, Zeduri A, Bassi G, Pongetti G, Angelini L, Giovinnazzo S, Garcia PM, et al. Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes. *J Cardiovasc Med (Hagerstown)*. 2022;23:264–71.
- [18] Cohen SL, Gianos E, Barish MA, Chatterjee S, Kohn N, Lesser M, Giannis D, Coppa K, Hirsch JS, McGinn TG, Goldin ME, Spyropoulos AC, Northwell Health COVID-19 Research Consortium. Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients. *Thromb Haemost*. 2021;121:1043–53.
- [19] Di Castelnuovo A, Costanzo S, Antinori A, Berselli N, Blandi L, Bonaccio M, Cauda R, Guaraldi G, Menicanti L, Mennuni M, Parruti G, Patti G, Santilli F, Signorelli C, Vergori A, Abete P, Ageno W, Agodi A, Agostoni P, Aiello L, et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study. *Thromb Haemost*. 2021;121:1054–65.
- [20] Ionescu F, Jaiyesimi I, Petrescu I, Lawler PR, Castillo E, Munoz-Maldonado Y, Imam Z, Narasimhan M, Abbas AE, Konde A, Nair GB. Association of anticoagulation dose and survival in hospitalized COVID-19 patients: a retrospective propensity score-weighted analysis. *Eur J Haematol*. 2021;106:165–74.
- [21] Rentsch CT, Beckman JA, Tomlinson L, Gellad WF, Alcorn C, Kidwai-Khan F, Skanderson M, Brittain E, King JT Jr, Ho YL, Eden S, Kundu S, Lann MF, Greevy RA Jr, Ho PM, Heidenreich PA, Jacobson DA, Douglas JJ, Tate JP, Evans SJW, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. *BMJ*. 2021;372:n311.
- [22] Shen L, Qiu L, Liu D, Wang L, Huang H, Ge H, Xiao Y, Liu Y, Jin J, Liu X, Wang DW, Peterson ED, He B, Zhou N. The association of low molecular weight heparin use and in-hospital mortality among patients hospitalized with COVID-19. *Cardiovasc Drugs Ther*. 2021;36:113–20.
- [23] Poli D, Antonucci E, Ageno W, Prandoni P, Palareti G, Marcucci R. Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register. *Intern Emerg Med*. 2022;17:1013–21.
- [24] Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, Áinle FN, Alomran F, Alayed K, Alsheef M, AlSumait F, Pompilio CE, Sperlich C, Tangri S, Tang T, Jaksa P, Suryanarayan D, Almarshoodi M, Castellucci LA, James PD, Lillicrap D, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. *BMJ*. 2021;375:n2400.
- [25] Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. *JAMA Intern Med*. 2021;181:1612–20.
- [26] ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR, Turgeon AF, Escobedo J, Huang DT, Bradbury CA, Houston BL, Kornblith LZ, Kumar A, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. *N Engl J Med*. 2021;385:790–802.
- [27] Sholzberg M, da Costa BR, Tang GH, Rahhal H, AlHamzah M, Baumann Kreuziger L, Ní Áinle F, Almarshoodi MO, James PD, Lillicrap D, Carrier M, Beckett A, Fralick M, Middeldorp S, Lee AYY, Thorpe KE, Negri EM, Cushman M, Jüni P. RAPID Trial Investigators. Randomized trials of therapeutic heparin for COVID-19: a meta-analysis. *Res Pract Thromb Haemost*. 2021;5:e12638.
- [28] Blondon M, Cereghetti S, Pugin J, Marti C, Darbellay Farhoumand P, Reny JL, Calmy A, Combescure C, Mazzolai L, Pantet O, Ltaief Z, Méan M, Manzocchi Besson S, Jeanneret S, Stricker H, Robert-Ebadi H, Fontana P, Righini M, et al. Therapeutic anticoagulation to

- prevent thrombosis, coagulopathy, and mortality in severe COVID-19: the Swiss COVID-HEP randomized clinical trial. *Res Pract Thromb Haemost.* 2022;6:e12712.
- [29] Muñoz-Rivas N, Aibar J, Gabara-Xancó C, Trueba-Vicente Á, Urbelz-Pérez A, Gómez-Del Olmo V, Demelo-Rodríguez P, Rivera-Gallego A, Bosch-Nicolau P, Perez-Pinar M, Rios-Prego M, Madridano-Cobo O, Ramos-Alonso L, Alonso-Carrillo J, Francisco-Albelsa I, Martí-Saez E, Maestre-Peiró A, Méndez-Bailón M, Hernández-Rivas JÁ, Torres-Macho J, et al. Efficacy and safety of tinzaparin in prophylactic, intermediate and therapeutic doses in non-critically ill patients hospitalized with COVID-19: the PROTHROMCOVID randomized controlled trial. *J Clin Med.* 2022;11:5632.
- [30] Stone GW, Farkouh ME, Lala A, Tinuoye E, Dressler O, Moreno PR, Palacios IF, Goodman SG, Esper RB, Abizaid A, Varade D, Betancur JF, Ricalde A, Payro G, Castellano JM, Hung IFN, Nadkarni GN, Giustino G, Godoy LC, Feinman J, et al. Randomized trial of anticoagulation strategies for noncritically ill patients hospitalized with COVID-19. *J Am Coll Cardiol.* 2023;81:1747–62.
- [31] Pilia E, Belletti A, Fresilli S, Lee TC, Zangrillo A, Finco G, Landoni G. full anticoagulation. The effect of heparin full-dose anticoagulation on survival of hospitalized, non-critically ill COVID-19 patients: a meta-analysis of high quality studies. *Lung.* 2023;201:135–47.
- [32] Morici N, Podda G, Biocchi S, Bonacchini L, Merli M, Trezzi M, Massaini G, Agostinis M, Carloti G, Saverio Serino F, Gazzaniga G, Barberis D, Antolini L, Grazia Valsecchi M, Cattaneo M. Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: the X-COVID-19 randomized trial. *Eur J Clin Invest.* 2021:e13735.
- [33] Zuily S, Lefèvre B, Sanchez O, Empis de Vendin O, de Ciano G, Arlet JB, Khider L, Terriat B, Greigert H, Robert CS, Louis G, Trinh-Duc A, Rispal P, Accassat S, Thiery G, Montani D, Azarian R, Meneveau N, Soudet S, Le Mao R, et al. Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial. *EClinicalMedicine.* 2023;60:102031.
- [34] Berger JS, Kornblith LZ, Gong MN, Reynolds HR, Cushman M, Cheng Y, McVerry BJ, Kim KS, Lopes RD, Atassi B, Berry S, Bochicchio G, de Oliveira Antunes M, Farkouh ME, Greenstein Y, Hade EM, Hudock K, Hyzy R, Khatri P, Kindzelski A, et al. Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial. *JAMA.* 2022;327:227–36.
- [35] RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet.* 2022;399:143–51.
- [36] Eikelboom JW, Jolly SS, Belley-Cote EP, Whitlock RP, Rangarajan S, Xu L, Heenan L, Bangdiwala SI, Luz Diaz M, Diaz R, Yusufali A, Kumar Sharma S, Tarhuni WM, Hassany M, Avezum A, Harper W, Wasserman S, Almas A, Drapkina O, Felix C, et al. Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. *Lancet Respir Med.* 2022;10:1169–77.
- [37] Kumar D, Kaimaparambil V, Chandralekha S, Lalchandani J. Oral rivaroxaban in the prophylaxis of COVID-19 induced coagulopathy. *J Assoc Physicians India.* 2022;70:11–2.
- [38] Kirkup C, Pawlowski C, Puranik A, Conrad I, O'Horo JC, Gomaa D, Banner-Goodspeed VM, Mosier JM, Zabolotskikh IB, Daugherty SK, Bernstein MA, Zaren HA, Bansal V, Pickering B, Badley AD, Kashyap R, Venkatakrishnan AJ, Soundararajan V. Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry. *J Med Virol.* 2021;93:4303–18.
- [39] REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF, Kornblith LZ, Kahn SR, Marshall JC, Kim KS, Houston BL, Derde LPG, Cushman M, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. *N Engl J Med.* 2021;385:777–89.
- [40] Goligher EC, Lawler PR, Jensen TP, Talisa V, Berry LR, Lorenzi E, McVerry BJ, Chang CH, Leifer E, Bradbury C, Berger J, Hunt BJ, Castellucci LA, Kornblith LZ, Gordon AC, McArthur C, Webb S, Hochman J, Neal MD, Zarychanski R, et al. Heterogeneous treatment effects of therapeutic-dose heparin in patients hospitalized for COVID-19. *JAMA.* 2023;329:1066–77.
- [41] Kanagaratnam P, Francis DP, Chamie D, Coyle C, Marynina A, Katritsis G, Paiva P, Szigeti M, Cole G, de Andrade Nunes D, Howard J, Esper R, Khan M, More R, Barreto G, Meneguz-Moreno R, Arnold A, Nowbar A, Kaura A, Mariveles M, et al. A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial. *J Thromb Haemost.* 2023;21:2213–22.
- [42] Spyropoulos AC, Connors JM, Douketis JD, Goldin M, Hunt BJ, Kotila T, Lopes RD, Schulman S, International Society on Thrombosis and Haemostasis. Good practice statements for antithrombotic therapy in the management of COVID-19. *J Thromb Haemost.* 2022;20:2226–36.
- [43] Perepu US, Chambers I, Wahab A, Ten Eyck P, Wu C, Dayal S, Sutamtewagul G, Bailey SR, Rosenstein LJ, Lentz SR. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial. *J Thromb Haemost.* 2021;19:2225–34.
- [44] INSPIRATION Investigators, Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, Sezavar SH, Payandemehr P, Dabbagh A, Moghadam KG, Jamalkhani S, Khalili H, Yadollahzadeh M, Riahi T, Rezaeifar P, Tahamtan O, Matin S, Abedini A, Lookzadeh S, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. *JAMA.* 2021;325:1620–30.
- [45] Labbé V, Contou D, Heming N, Megarbane B, Razazi K, Boissier F, Ait-Oufella H, Turpin M, Carreira S, Robert A, Monchi M, Souweine B, Preau S, Doyen D, Vivier E, Zucman N, Dres M, Fejjal M, Noel-Savina E, Bachir M, et al. Effects of standard-dose prophylactic, high-dose prophylactic, and therapeutic anticoagulation in patients with hypoxemic COVID-19 pneumonia: the ANTICOID randomized clinical trial. *JAMA Intern Med.* 2023;183:520–31.
- [46] Oliynyk O, Barg W, Slifarczyk A, Oliynyk Y, Dubrov S, Gurianov V, Rorat M. Comparison of the effect of unfractionated heparin and enoxaparin sodium at different doses on the course of COVID-19-associated coagulopathy. *Life (Basel).* 2021;11:1032.
- [47] Bohula EA, Berg DD, Lopes MS, Connors JM, Babar I, Barnett CF, Chaudhry SP, Chopra A, Ginete W, Ieong MH, Katz JN, Kim EY, Kuder JF, Mazza E, McLean D, Mosier JM, Moskowitz A, Murphy SA, O'Donoghue ML, Park JG, et al. Anticoagulation and antiplatelet therapy for prevention of venous and arterial thrombotic events in critically ill patients with COVID-19: COVID-PACT. *Circulation.* 2022;146:1344–56.
- [48] REMAP-CAP Writing Committee for the REMAP-CAP Investigators, Bradbury CA, Lawler PR, Stanworth SJ, McVerry BJ, McQuilten Z, Higgins AM, Mouncey PR, Al-Beidh F, Rowan KM, Berry LR, Lorenzi E, Zarychanski R, Arabi YM, Annane D, Beane A, van Bentum-Puijck W, Bhimani Z, Bihari S, Bonten MJM, et al. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. *JAMA.* 2022;327:1247–59.
- [49] Berger JS, Neal MD, Kornblith LZ, Gong MN, Reynolds HR, Cushman M, Althouse AD, Lawler PR, McVerry BJ, Kim KS,



- Baumann Kreuziger L, Solomon SD, Kosiborod MN, Berry SM, Bochicchio GV, Contoli M, Farkouh ME, Froess JD, Gandotra S, Greenstein Y, et al. Effect of P2Y12 inhibitors on organ support-free survival in critically ill patients hospitalized for COVID-19: a randomized clinical trial. *JAMA Netw Open*. 2023;6:e2314428.
- [50] Writing Committee for the REMAP-CAP Investigators, Higgins AM, Berry LR, Lorenzi E, Murthy S, McQuilten Z, Mouncey PR, Al-Beidh F, Annane D, Arabi YM, Beane A, van Bentum-Puijk W, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Burrell A, Buzgau A, Buxton M, Charles WN, et al. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. *JAMA*. 2023;329:39–51.
- [51] Bradbury CA, Lawler PR, McVerry BJ, Zarychanski R. Continuation of therapeutic dose heparin for critically ill patients with COVID-19. *Intensive Care Med*. 2023;49:873–5.
- [52] Sytema JG, Loef BG, Loovers HM, Boer M, Touw DJ, van Hulst M. The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin. *Res Pract Thromb Haemost*. 2023;7:100185.
- [53] GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl J Med*. 1993;329:673–82.
- [54] Wang TY, Wahed AS, Morris A, Kreuziger LB, Quigley JG, Lamas GA, Weissman AJ, Lopez-Sendon J, Knudson MM, Siegal DM, Kasthuri RS, Alexander AJ, Wahid L, Atassi B, Miller PJ, Lawson JW, Patel B, Krishnan JA, Shapiro NL, Martin DE, et al. Effect of thromboprophylaxis on clinical outcomes after COVID-19 hospitalization. *Ann Intern Med*. 2023;176:515–23.
- [55] Giannis D, Allen SL, Tsang J, Flint S, Pinhasov T, Williams S, Tan G, Thakur R, Leung C, Snyder M, Bhatia C, Garrett D, Cotte C, Isaacs S, Gugerty E, Davidson A, Marder GS, Schnitzer A, Goldberg B, McGinn T, et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. *Blood*. 2021;137:2838–47.
- [56] Ramacciotti E, Barile Agati L, Calderaro D, Aguiar VCR, Spyropoulos AC, de Oliveira CCC, Lins Dos Santos J, Volpiani GG, Sobreira ML, Joviliano EE, Bohatch Júnior MS, da Fonseca BAL, Ribeiro MS, Dusilek C, Itinose K, Sanches SMV, de Almeida Araujo Ramos K, de Moraes NF, Tierno PFGMM, de Oliveira ALML, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. *Lancet*. 2022;399:50–9.
- [57] Courtney LA, Trujillo TC, Saseen JJ, Wright G, Palkimas S. Evaluation of the clinical impact of thromboprophylaxis in patients with COVID-19 following hospital discharge. *Ann Pharmacother*. 2022;56:981–7.
- [58] Li P, Zhao W, Kaatz S, Latack K, Schultz L, Poisson L. Factors associated with risk of postdischarge thrombosis in patients with COVID-19. *JAMA Netw Open*. 2021;4:e2135397.
- [59] Arachchilage DJ, Rajakaruna I, Odho Z, Makris M, Laffan M. Impact of thromboprophylaxis on hospital acquired thrombosis following discharge in patients admitted with COVID-19: multicentre observational study in the UK. *Br J Haematol*. 2023;202:485–97.
- [60] Gibson CM, Spyropoulos AC, Cohen AT, Hull RD, Goldhaber SZ, Yusen RD, Hernandez AF, Korjian S, Daaboul Y, Gold A, Harrington RA, Chi G. The IMPROVEDD VTE risk score: incorporation of D-dimer into the IMPROVE score to improve venous thromboembolism risk stratification. *TH Open*. 2017;1:e56–65.
- [61] OpenSAFELY Collaborative, Tazare J, Walker AJ, Tomlinson LA, Hickman G, Rentsch CT, Williamson EJ, Bhaskaran K, Evans D, Wing K, Mathur R, Wong AY, Schultze A, Bacon S, Bates C, Morton CE, Curtis HJ, Nightingale E, McDonald HI, Mehrkar A, et al. Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19 in England: a descriptive cohort study within the OpenSAFELY platform. *Wellcome Open Res*. 2022;7:142.
- [62] Houghton DE, Wysokinski WE, Padnos LJ, Shah S, Wysokinska E, Pruthi R, Ghorbanzadeh A, Ashrani A, Sridharan M, McBane RD, Padmanabhan A, Casanegra AI. Venous thromboembolism after COVID-19 vaccination in patients with thrombophilia. *Am J Hematol*. 2023;98:566–70.
- [63] Bissola AL, Daka M, Arnold DM, Smith JW, Moore JC, Clare R, Ivetic N, Kelton JG, Nazy I. The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia. *Blood Adv*. 2022;6:4228–35.
- [64] Favaloro EJ, Clifford J, Leitinger E, Parker M, Sung P, Chunilal S, Tran H, Kershaw G, Fu S, Passam F, Ahuja M, Ho SJ, Duncan E, Yacoub O, Tan CW, Kaminski L, Modica N, Pepperell D, Ballard L, Clarke L, et al. Assessment of immunological antiplatelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: a multicenter study comprising 1284 patients. *J Thromb Haemost*. 2022;20:2896–908.
- [65] Mouta Nunes de Oliveira P, Mendes-de-Almeida DP, Bertollo Gomes Porto V, Crespo Cordeiro C, Vitiello Teixeira G, Saraiva Pedro R, Roberto Gomes Takey P, Kegele Lignani L, Reis Xavier J, Cardoso Doria da Gama V, Amorim Filho L, Emoingt Furtado B, Santa Maria A, Dahrug Barros T, Neves Waite Freitas L, Dos Santos Pereira T, Lima Abreu D, Bernardes Ramos M, Gabe C, Arnold D, et al. Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: description of a series of 39 cases in Brazil. *Vaccine*. 2022;40:4788–95.
- [66] Thiele T, Weisser K, Schönborn L, Funk MB, Weber G, Greinacher A, Keller-Stanislawski B. Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany. *Lancet Reg Health Eur*. 2022;12:100270.
- [67] Uzun G, Althaus K, Hammer S, Wanner Y, Nowak-Harnau S, Enkel S, Bakchoul T. Diagnostic performance of a particle gel immunoassay in vaccine-induced immune thrombotic thrombocytopenia. *Haemostaseologie*. 2023;43:22–7.
- [68] Kim AY, Woo W, Yon DK, Lee SW, Yang JW, Kim JH, Park S, Koyanagi A, Kim MS, Lee S, Shin JI, Smith L. Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a systematic review and meta-analysis. *Int J Infect Dis*. 2022;119:130–9.
- [69] Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, Rampotas A, Ambler G, Makris M. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. *N Engl J Med*. 2021;385:1680–9.
- [70] Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, Yeo JM, Zhang L, Hassan-Smith G, Jones M, Hutchcroft C, Hobson E, Warcel D, White D, Ferdinand P, Webb A, Solomon T, Scully M, Werring DJ, Roffe C, et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. *Lancet*. 2021;398:1147–56.
- [71] Scutelnic A, Krzywicka K, Mbroh J, van de Munckhof A, van Kammen MS, de Sousa DA, Lindgren E, Jood K, Günther A, Hiltunen S, Putaala J, Tiede A, Maier F, Kern R, Bartsch T, Althaus K, Ciccone A, Wiedmann M, Skjelland M, Medina A, et al. Management of cerebral venous thrombosis due to adenoviral COVID-19 vaccination. *Ann Neurol*. 2022;92:562–73.
- [72] Mendes-de-Almeida DP, de Oliveira PMN, Porto VBG, Pedro RS, Takey PRG, Lignani LK, Vitiello Teixeira G, Pereira TDS, Abreu DL, Xavier JR, Castro TDM, Melo de Amorim Filho L, Sousa Maia ML. Vaccine-induced immune thrombotic thrombocytopenia post COVID-19 booster vaccination in Brazil: a case series. *Res Pract Thromb Haemost*. 2023;7:102243.



- [73] Khan F, Tritschler T, Kimpton M, Wells PS, Kearon C, Weitz JI, Büller HR, Raskob GE, Ageno W, Couturaud F, Prandoni P, Palareti G, Legnani C, Kyrle PA, Eichinger S, Eischer L, Becattini C, Agnelli G, Vedovati MC, Geersing GJ, et al. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis. *J Thromb Haemost.* 2021;19:2801–13.
- [74] Khan F, Rahman A, Carrier M, Kearon C, Weitz JI, Schulman S, Couturaud F, Eichinger S, Kyrle PA, Becattini C, Agnelli G, Brighton TA, Lensing AWA, Prins MH, Sabri E, Hutton B, Pinede L, Cushman M, Palareti G, Wells GA, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. *BMJ.* 2019;366:l4363.
- [75] Lee CSM, Liang HPH, Connor DE, Dey A, Tohidi-Esfahani I, Campbell H, Whittaker S, Capraro D, Favaloro EJ, Donikian D, Kondo M, Hicks SM, Choi PY, Gardiner EE, Clarke LJ, Tran H, Passam FH, Brighton TA, Chen VM. A novel flow cytometry pro-coagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia. *Blood Adv.* 2022;6:3494–506.

#### SUPPLEMENTARY MATERIAL

The online version contains supplementary material available at <https://doi.org/10.1016/j.jtha.2024.02.011>